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Five Framings – One Entity?
The Political Ethics of Human
Embryonic Stem Cells
Torben Hviid Nielsen
Following their initial derivation in 1998, human embryonic stem cells have been
presented in five dominant framings. The original framings as a breakthrough in ba-
sic research and a medical hope were both intended and orchestrated to anticipate
and overrule the old bioethical concerns. The third framing nonetheless questioned
the legitimacy of the bare laboratory research from day one. Two subsequent framings
presented adult stem cells as Nature’s own solution and cloning as Mankind’s techno-
fix solution, i.e. as alternative points of passages to the ethical concerns, but they did
not succeed to regain the agenda and the public discourse. The five framing are thus
elements of a still unclosed encounter over-determined by (bio)politics. Finally the
framing of “facts” of nature, technological “artefacts” and social “construct” is discussed
in the light of recent interpretations of stem cells as “state” rather than as “entity”, thus
indicating that no single entity is to be found behind the five framings.
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page, 2238-2239). In November 1999 a
committee under the American Associa-
tion for the Advancement of Science con-
cluded that stem cell research “raises
ethical and political concerns, but these
are not unique to stem cell research”
(AAAS, 1999: iv). Two years later a com-
mittee under the National Research
Council stated that “the stem cell debate
has led scientists and nonscientists alike
to contemplate profound issues, such as
who we are and what makes us human
beings” (NRC, 2001: xi).
The 1998 Summer-issue of Technology
Review disclosed the ongoing pioneer
research on human embryonic stem
cells under the front-page heading
“Biotech Taboo”… “The troubled Hunt
for the ultimate Cell,… that could be
used to grow any type of human replace-
ment tissue” (Regalado, 1998: front-
page, 34). Barely a year and a half later
the front-page of the 1999 Christmas-is-
sue of Science promoted stem cells as the
“Breakthrough of the Year,… capturing
the Promise of Youth” (Vogel, 1999: front-
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Human embryonic stem cells have –
together with cloning – become the most
promising, as well as the most contro-
versial, amongst the many new and
emerging biotechnologies. After they left
the laboratories in 1998 to become part
of public debate five framings have
dominated their presentation and dis-
cussion. The first public pronounce-
ment was well orchestrated as progress
in basic science, and the second framing
as a medical hope was often presented
as just the other, applied, side of it. The
two original framings were partly in-
tended to prevent the reoccurrence of
traditional ethical concerns, which nev-
ertheless questioned the first two from
the very beginning. Subsequently, the
scientific community itself suggested
two “solutions” to the reoccurring ethi-
cal concerns: in a fourth framing offer-
ing the potentials of the adult stem cells
as Nature’s own solution and in a fifth
framing offering therapeutic cloning as
Mankind’s techno-fix.
The main topic is the intended crea-
tion of and the relation between the five
framings, their interplay in the public
narrative and discourse, as well as the
partly unforeseen and unintended con-
sequences thereof. None of the five
framings have succeeded to bring a clo-
sure to the controversy. All remain part
of the still vibrant scientific and public
debate, but they are utilized in favour of
evaluations so varied and regulations so
conflicting that compromises are diffi-
cult to formulate and attain. They also
appear diverse and partly apart, to the
extent where geneticist and biologists
are now questioning whether one and
the same well defined biological entity
is to be found behind all of them.
Pioneer STS-articles by Trevor Pinch
and Wiebe Bijker conceptualized and re-
told the story of the high-wheel Ordinary
bicycle and Bakelite as the framing, de-
sign and eventually production of new
technological artefacts or inventions.
After decades of competition between a
variety of designs for the bicycle and
methods for the production of pre-
bakelite plastic, the high-wheel Ordinary
bicycle and Baekeland’s patents of 1907
finally brought success to a single fram-
ing and design and thus eventually also
closure to the flexibility and controver-
sies (Pinch and Bijker, 1989; Bijker, 1989).
The term “framing” is throughout this
article used in relation to the public rep-
resentation of an entity of nature, such
as in media-studies (Evans, 2002); to the
mobilization of collective actors and so-
cial movements, such as in the social
sciences (Benford and Snow, 2002) – not,
as in the case of Pinch and Bijker, to des-
ignate the design and creation of tech-
nological artefacts. The eventually suc-
cessful high-wheel bicycle and Bakelite
both had their possible alternative
framings and artefacts (as e.g. the Kan-
garoo bicycle and Ivoride/Xylonite or
Celluloid), whereas the five framings of
human embryonic stem cells, to be dis-
cussed below, all assume or presume to
address different aspects and evalua-
tions of the very same biological entity.
Instead of diverse framings leading to
different technological artefact, the
same entity of nature is presented to the
public in five different framings indicat-
ing different horizons and valuations. Up
until now, none of the five framings have
become dominant and “successfully”,
able to exclude the others and close the
flexibility and controversy, in the same
way as the high-wheel bicycle and
Bakelite did.
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First framing. The Derivation of a
Scientific Discovery
During the years from 1995 to 1998 labs
in Wisconsin and Baltimore were the
sites of the initial derivation of human
embryonic stem cells, but their first pub-
lic presentation took place via internet
from the rented offices of their coordi-
nator and financier, the entrepreneur Dr.
Michael West at Geron Corporation, who
had licensed the cells worldwide, or-
chestrated the framing of their first pub-
lic announcement as a “scientific discov-
ery” and “progress in basic research”
very thoroughly. Two press releases from
the company provided the key back-
ground information for the printed
press’ front-page news that “Scientist
Found Cells at Root of Human Life” on
November 6, 1998 (The New York Times).
The press releases referred back to two
prestigious scientific publications: An
article in Science by professor James A.
Thomson and colleagues from Univer-
sity of Wisconsin, who had isolated hu-
man embryonic stem (hES) cells from
the inner cell mass of human embryos
at the blastocyst stage (Thomson et al.,
1998), and another article in Proceedings
of the National Academy of Science by
professor John D. Gearhart and col-
leagues from John Hopkins University,
Baltimore, who had isolated human
embryonic germ (hEG) cells from foetal
tissues obtained from terminated preg-
nancies (Shamblott et al., 1998).
The passage from the scientific peri-
odicals via the press releases to the front-
page news was, however, also an essen-
tial translation and reframing. Stem
cells, especially from bone marrow, had
been known and used in cancer treat-
ment since the 1950s, and embryonic
stem cells had been derived from mice
in 1981 (Evans et al., 1981) and from pri-
mates in 1995 (Gearhard et al., 1995).
The “novelty” presented in the scientific
publications was thus neither the exist-
ence of stem cells as such, nor of embry-
onic stem cells or even of human embry-
onic stem cells, but merely the success-
ful “derivation” of human embryonic
stem cells, which consequently was pre-
sented as technical and practical know-
how more than as scientific and system-
atic knowledge.
The two articles do not have the aura
of a new theoretical insight nor do they
proclaim any controversial break-
through. The definition of the cell lines
and the operational criteria for their
derivation are both conveyed un-
changed from the preceding experi-
ments with mice and primates. The es-
sential content of the two articles is a
summary and documentation of re-
search-protocols with references to pre-
ceding studies. Description and docu-
mentation of practical procedure in the
laboratories take precedence over con-
ceptual clarification and explanations.
Large passages of the two articles thus re-
semble a mix of cookbook and manual,
conceptual trivialities and complicated
technicalities: those were the ingredi-
ents and this is how we proceeded at the
lab-bench. By way of a not untypical ex-
ample:
Cells were grown in DMEM (GIBCO/
BRL) supplemented with 15% fetal bo-
vine serum (HyClone), 0,1 mM nones-
sential amino acids (GIBCO/BRL),
0,1mM 2-mercaptoethanol (Sigma), 2
mM glutamine… Cultures were grown
in 5% or 8% CO
2
, 95% humidity and
were routinely passaged every 7 days
after disaggregation with 0.05%
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trypsin/0.53 mM EDTA (GIBCO/BRL)
or 0,25% trypsin at 37° C for 5-10 min…
Cells prepared for cytogenetic analysis
were incubated in growth media with
0.1. µg/ml of Colcemid for 3-4 hr,
trypsinized, resuspended in 0.075 M
KCl, and incubated for 20 min at 37° C,
then fixed in 3:1 methanol/acctic acid
(Shamblott et al., 1998:13727).
The articles do not claim to have found
or discovered any new or even unex-
pected entity or substance, but rather to
have demonstrated that an expected
entity can be kept and maintained in a
certain form: isolated, cultivated and
expressed. The two research-teams had
successfully adapted and replicated or
copied in human cells, what had previ-
ously been attained in cells from mice
and primates. The articles thus consti-
tuted human embryonic stem cells as a
new object for science analogous to the
way Gregory Mendel constituted genet-
ics (and Crick & Watson later DNA) as
objects for science (Foucault, 1971), but
neither theoretical implications nor
practical applications were part of the
presentation.
The triangle of collaboration between
the private company Geron, the partly
public universities and their partly
outsourced research-teams was a re-
sponse to the political reality, that the
USA had had a de facto ban on public
funding of research since 1996 “in which
a human embryo or embryos are de-
stroyed, discarded, or knowingly sub-
jected to risk of injury or death greater
than that allowed for research on fetuses
in uteri.” Congress had taken the decision
ad hoc as the Dickey-Wicker amendment
to Department of Health and Human
Services annual budget – and against the
recommendations of the National Insti-
tute of Health and the Clinton-adminis-
tration. As only the use of public funding
was forbidden, a paradoxical conse-
quence was, however, quoting Dr. Ronald
Green, a key advisor to the Clinton-ad-
ministration.
…[that] although much of the previous
animal research on ES cells that had led
to Thomson’s achievements was feder-
ally financed, the commercial benefit
would now be in private hands (Green,
2001: 9).
Geron Corporation had been founded by
Dr. Michael West in 1990. Following the
publication of the derivation of embry-
onic stem cells from primates in 1995,
Geron had funded the research of
Thomson and Gearhart, as well as Pro-
fessor Roger Peterson, University of Cali-
fornia, San Francisco – considered by
many the most promising candidate to
succeed (Regalado, 1998: 38). The invest-
ments in funding for licenses turned out
to be an immediate financial success.
Two applications for patents were filed
well in advance of the scientific publi-
cation and subsequently approved. On
the very day of announcement, stocks
rose from $ 6 to $ 23. One month later,
convertible debentures worth $ 15 mil-
lion were sold to venture capitalists.
Yet, a fourth type of text had preceded
the triangle of publications behind the
first public announcement. The articles
in the prestigious scientific journals both
rounded off with reservations character-
istic of the genre, in the words of
Thomson and colleagues: “Substantial
advances in basic developmental biol-
ogy are required to direct Es cells effi-
ciently to lineages of human clinical im-
portance” (Thomson et al., 1998: 1147).
Two patent-applications were, however,
filed well in advance, and they presented
the findings with a confidence and firm-
Science Studies 1/2005
34
ness fare from the modesty and reserva-
tions in the scientific articles. Both ap-
plications were “continuation-in-part”
of earlier applications. They were more
detailed, fare longer than the articles and
the “Scientists” were completed in the
standard formula as “Inventors”. Gear-
hart’s application (United States Patent,
1998a) had the largest number of formal
“Claims”, thirty-six, all concerning meth-
ods of producing and/or maintaining
“human pluripotent embryonic germ
cells”. The eleven claims in Thomsen’s ap-
plication (United States Patent, 1998b)
were presented in another “logic”. The
first eight claims cover different variants
of “a purified preparation of pluripotent
human embryonic stem cells”, the two
next methods of isolating such cell lines,
and last the cell line developed by the
method.
The rationale behind the comprehen-
sive claims is the quest for a maximum
of legal protection. And the criteria for
patentability may have determined even
the choice of the key concept or techni-
cal term “derivation”. The term “deriva-
tion” was not used in the articles report-
ing the previous use of identical proce-
dures and techniques on mice and pri-
mates; the key terms here were “isola-
tion” and “establishment”, partly used as
synonyms. But “derivation” was the key
term also in the 1997-article announc-
ing the cloning of a “viable offspring”, the
sheep Dolly (Wilmut et al., 1997). Fol-
lowing the new terminology or the new
use of old terms, human embryonic
stem cells and cloned sheep were both
presented as “derived”. The two promi-
nent cases are only examples of a gen-
eral trend in the prestigious scientific
periodicals during the 1990s (see Fig. I.).
“Isolation” and “establishment” were the
most frequently used terms in the first
half of the decade, but during the sec-
ond half “derivation” took over as the
most frequent. The significant change
took place just around the years when
the sheep Dolly and the human embry-
onic stem cells both were termed as “de-
rived”.
The new trend might be a momentary
conjuncture, but the relative increase in
the use of the term “derivation” at the
expense of “isolation” and “establish-
ment” during the 1990s is both signifi-
cant and meaningful. The term “deriva-
tion” was increasingly used to describe
the isolation, cultivation and expression
of embryonic stem cells, as well as the
cloning of viable offspring, i.e. two very
different phenomena, but the two most
promising and controversial of the many
new biotechnologies. The new tendency
is “real”, but we don’t know the degree to
which it reflects substantial changes in
research priorities, mere changes in edi-
torial criteria or even merely a change of
habitual wording. Asked for the causes
of the change, the typical answer from a
handful of prominent researchers in the
field was that they had not previously
been aware of any such change; that the
change nevertheless seemed plausible,
but that it did not require any special
explanation. “It is quite simply the con-
cept we use.” The diverse and escalating
use of the term “derivation” might ap-
pear irrelevant or even trivial to the
working scientists, but the precedence
from the terms prehistory in patenting
of organic chemistry is well known and
acknowledged among lawyers. The
“derivation” of a substance was suffi-
cient to satisfy one of the three general,
but crucial, criteria for patentability. Al-
though still a product of nature, since it
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would not have existed in the new form
without the intervention of science, a
derived entity was considered also a
product of ingenuity and thus a patent-
able invention.1
Second Framing. The Promise of a
Regenerative Medicine
The second framing of the human em-
bryonic stem cells as a medical hope, the
promises of regenerative medicine, was
often presented as just the other side of
the progress in basic knowledge, as the
step from “pure” to “applied” science.
The principal agents were the same, but
alongside the scientific community and
venture capitalists the appeal was di-
rected more towards the general public
and authorities as The National Institute
of Health. Both steps in this widespread
and still persuasive, but very traditional,
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Isolation & Establishment Derivation
Figure I. From isolation towards derivation.
The relative occurrence of “isolation” and “establishment” versus “derivation” in Nature, Proc.
Nat. Acad. Sci. and Sciene, 1990-2001.
Source: Data-search in “Titles” in the three periodicals from 1990 to 2001.
Truncations used were “Isolat#”, “Establish#” and “Deriv#”.
N = 1137, with 266 in 1990-91, 214 in 1992-92, 209 in 1994-95, 161 in 1996-97, 162 in 1998-99
and 125 in 2000-2001.
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presentation of the novelty are, however,
deceptive. Down to the choice of basic
terminology desired ends were built and
calculated into the “discovery” from the
first design of the laboratory studies. The
“application” is also a redefinition or
translation of health and illness, life and
death, from existential and social terms.
The applied potential of embryonic
stem cells was presented as the bio-
technical mean to retain, modify or even
undo apoptosis, i.e. the programmed cell
death, which (beginning with Leonard
Hayflick and Paul Morehead’s proposal
in 1961 that “cancerous” cell lines were
the only immortal cells, whereas “nor-
mal” cells had a finite lifespan) had re-
placed the immortality of cell lines as the
paradigmatic understanding. Social
death and euthanasia had, according to
Hannah Landecker, become
“cellular, even to the extent that a cell
can commit altruistic suicide or die by
interaction with another cell in the
Kevorkian option”... Death was rede-
fined as a mixed metaphor, marking a
“radical shift in biological knowledge in
the late twentieth century, from an
oppositional model of life and death
to one in which cell death is integral
to the ongoing life of the organism.”
(Landecker, 2003: 23-24).
All stem cells, also adult, do  produce the
enzyme telomerase, which was isolated
for the first time in 1989 and maintains
the non-coding bits of DNA attached to
the end of each chromosome (Dwayne
et al., 1989). With a biochemical expla-
nation for philosophers, telomerase “re-
sets the cell’s chromosomal clock” and
“prevents the timed death suffered by
most differentiated cells”. Stem cells
hence have the capacity for “prolonged
self-renewal”; they are able to produce
“at least one type of highly differentiated
or specialized descendant.” (Green,
2001: 35) Yet, the emerging new para-
digm ascribes three additional capaci-
ties to embryonic stem cells: they are
pluripotent (able to differentiate to all
types of tissues in the body); they are
malleable (can be manipulated without
loosing the structure of the cell); and
they are immortal (able to continue dif-
ferentiation apparently unlimited)
(Weismann, 2000; Fuch and Segre, 2000;
Chiu and Rao, 2003). The three unique
capacities were the background for Sci-
ence’s presentation of human embryonic
stem cells as the 1999-breakthrough of
the year.
“If it lives up to its early promise, it may
one day restore vigour to aged and dis-
eased muscles, hearts, and brains – per-
haps even allowing humans to com-
bine the wisdom of the old age with the
potential of youth”... [They] “may one
day be used to treat human diseases in
all sort of ways, from repairing dam-
aged nerves to growing new hearts and
livers in the laboratory; enthusiasts en-
vision a whole catalog of replacement
parts” (Vogel, 1998: 2238).
The three potentials considered unique
to embryonic stem cells add up to the
scenario of “regenerative medicine”,
which enlarges the scope of medical
therapy “from simply halting the pro-
gression of acute or chronic disease to
include restoration of lost organ func-
tions”. Bypassing surgery’s interventions
in the body, as well as the side effects of
pharmaceuticals, regenerative medicine
will - according to Dr. Thomas Okarma,
who had succeeded West as CEO of
Geron - “be a totally new value paradigm
for clinical therapeutics.” Okarma was
thus able to revolve the moral concern
and argument against the bioethicists
themselves. “Not to develop the technol-
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ogy would do great harm to over 100
million patients in the U.S. alone.”
(Okarma, 2001: 3). The number origi-
nates from an overview over the poten-
tial US patient population for stem cell-
based therapies, which is estimated 58
million with cardiovascular diseases, 30
million with autoimmune diseases, 16
million with diabetes, 10 million with
osteoporosis, and 8.2 million with can-
cer (Perry, 2000). The twisted optic ac-
quits the optimistic scientists in order to
make the sceptic bioethicists, willing to
deprive one third of the population their
cure, the real threat to real morality. Stem
cells thus acknowledge or confirm the
cellular level as the space or place of
death (Landauer, 2003), but besides they
offer themselves as the biomedical
means able to postpone or ultimately
undo cellular death.
Geron’s strategy has been character-
ized as “a redefinition of the human and
the social in which social responsibility
for health risks becomes biologized in
order to be industrialized” (Franklin,
2003: 123), a characterization in accord-
ance with Technology Review’s scenario
of “the human body shop” a decade from
now:
...an elderly man gets the grim news
that his heart is rapidly decaying and
that the left ventricle – the chamber
that squeezes blood out to the body –
needs to be replaced. His physician
takes a biopsy of the heart cells that are
still healthy and ships the tissue to a lab
that is really an organ factory. There,
workers use that patient’s own cells and
special polymers to fashion and grow a
replacement part – certified by the origi-
nal manufacturer. In three months, the
new ventricle is frozen, packaged and
sent to the hospital, where the patient
undergoes a standard surgical proce-
dure: the insertion of a living implant
created from his own tissue (Garr, 2001:
73).
The aura is high-tech, but the medical
use of embryonic stem cells is presented
as low intervention. The stem cells are
“organic”, i.e. the body’s own internal
healing mechanisms, “personal”, i.e.
one’s own, and “clean”, i.e. uncontami-
nated. But the real “magic” is the prom-
ise to break the arrow of time. “The im-
mortal Cell” is a shortcut to “The eter-
nal Life”. Destiny and fate are no longer
untouchable. Regenerative medicine is
high-tech utilization of the individuals
own embryonic stem cells as cure against
the otherwise unavoidable apoptosis of
the cells. Science and medicine promise
to accomplish here and now, what reli-
gion in the past barely believed possible
in the next world. Life is about to become
reversible or restorable, the permanent
beginning or the continuous renewal.
The hopes of “there and then” will be-
come the reality of “here and now” (Al-
exander, 2003; Hall, 2003).
Medical hopes and expectations are
high and hype, but the “applied” reality
is – at least up to now – a “proof of prin-
ciples”. Experiments in vitro and with
model-animals confirm the principle:
new tissues can differentiate and old
ones can be restored. The step from sci-
entific principle to medical practice is,
however, also a question of degree and
type of differentiation, density and in-
tensity, compatibility, targeting, and
possible side-effects. The old blood-
forming stem cells in bone marrow
(HSC) are still “the only type of stem cell
commonly used for therapy” (National
Institute of Health, 2003).
The severe shadow and potential
backlash hanging over the medical hope
is over-selling, promising too much too
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fast. Even the pioneering-scientists soon
warned of the backlash likely to come.
As early as 2002, Prof. Thomson was
quoted for not “looking forward to the
backlash 3 years from now when people
say, ‘What happened to stem cells?’ …We
need to educate the public that science
takes a long time” (Holden and Vogel,
2002: 2119). But entrepreneurs, such as
West, were eager to insist on the non-
scientific, and thus unnecessary, charac-
ter of all obstacles. “We have the basic
discoveries within our reach to put re-
generative medicine into the hand of
physicians. We are missing only two
components – an organized effort and
time” (West, 2003: 220).
Third Framing. Playing God? Old
(Bio)ethical Concerns in New Voices
Emphasizing the progress in basic re-
search and the hope for cure of illness,
the two initial framings were also antici-
pating strategies intended to trump and
overrule the expected moral concerns.
The two framings succeeded to counter-
balance, but they were unable to neu-
tralize the critique, which questioned
the very legitimacy of the basic labora-
tory research from day one. If science
was about to replace religion as the ex-
planation of life, then Christian (or
Creationist) religion was soon to return
accusing the new technologies of “play-
ing God”. The most prominent opponent
was the Vatican, but the recently inaugu-
rated U.S. president, Republican George
W. Bush, followed along the same line. On
August 9, he addressed the nation broad-
cast primetime from Crawford Texas to
discuss the “complex and difficult issue,
an issue that is one of the most profound
of our time” (Bush, 2001). His speech
hinted to and utilized the two arguments
most frequently used by opponents and
sceptics.
The first and foremost argument gains
its immanent strength by ascribing a
special moral status to the embryo. The
Christian background is manifest in the
President’s characterization of the em-
bryo as “a sacred gift from our Creator”.
Most believers in and users of the argu-
ment consider the status of the embryo
as emerging gradually (increasing from
some time after fertilization to the full
born baby), but a more radical version
consider the status as absolute and be-
ginning from fertilization. The Presi-
dent’s wording of the argument alludes
to the absolute version. “The beginning
of Life” should also be “The end of Sci-
ence.” But the President is politician
enough not to take an explicit stand in
the controversial dispute between the
two versions splitting the supporting re-
ligious communities.
The second moral argument alluded
to by the President is a more philosophi-
cal and formal maxim as regards the re-
lation between means and ends. The
maxim is usually traced back or ascribed
to Immanuel Kant’s practical imperative,
but the President’s version is another.
“Even the most noble ends do” in the
wording of the President “not justify any
means”. The Presidents open-ended ver-
sion is an anticipation of its own appli-
cation. The casuistic question is whether
the “most noble ends” (as a healthier or
prolonged life) can justify “any means”
(as the destruction of embryos to harvest
required stem cells)?
A strict interpretation and radical ap-
plication of the two arguments pre-
scribes a “No” or a “Ban” to all research
using human embryonic stem cells. The
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status of the Cell is violated and the
maxim of the Philosopher infringed.
Endorsed with an absolute status the
“embryo” resists its own use in science.
The technologically unavoidable is con-
sequently morally untouchable, the re-
quired source morally problematic. Eth-
ics stands versus science and science
versus ethics. No compromise seems
possible. But instead of the absolute ban
indicated by his rhetoric and supposed
by his arguments the president con-
cluded
…that we should allow federal funds to
be used for research on these existing
stem cell lines (more than 60 lines as a
result of private research), where the
life and death decision has already
been made (Bush, 2001).
The unexpected conclusion was in-
tended as a political balance offering
concessions to the most influential in-
terest-groups and their lobbyists: the
proponents were offered (some) stem
cell lines to work with, and the oppo-
nents were assured that no new demand
for embryos would be created. Both
sides were, however, soon to designate
their respective concessions as unsatis-
factory. Scientists complained that the
available stem cell lines were too few and
not pure enough. The religious commu-
nities accused the use of already exist-
ing lines of being a double moral stand-
ard and even bioethicists, such as Arthur
Caplan, denounced the decision as a
“fuzzy logic” utilized by the administra-
tion in “a political calculation to use op-
position to stem-cell research and clon-
ing as a low-risk stalking horse to ad-
vance its anti-abortion agenda and se-
cure support among its most avid anti-
abortion constituents” (Caplan, 2004).
As decided upon, but unsettled and
postponed, human embryonic stem
cells remained an issue also during the
next presidential campaign in 2004. The
Democratic candidate John Kerry prom-
ised to “overturn the ban on federal
funding of research on new stem cell
lines, … he will allow doctors and scien-
tists to explore their full potential with
the appropriate ethical oversight. Pa-
tients and their families should no
longer be denied the hope that this new
research brings” (Kerry and Edwards,
2004). Kerry utilized the first two of the
five framing discussed here, i.e. science
as a necessary precondition for useful
medicine. The five arguments in the
press release stating his position were
thus able to circumvent the controver-
sial ethical issues. The first argument was
political, an appeal to consensus: “Stem
cell research has broad bipartisan sup-
port.” The last argument concerned
competitiveness: U.S.A. is “losing lead-
ership in stem cell research”. The three
remaining arguments were all technical
criticisms of Bush’s decision as not only
insufficient, but also unimplemented.
Fewer cell lines than promised were
available; they were contaminated with
mouse cells; and other cells were not
available. Apart from a few empty inser-
tions, ethical issues were unmentioned
– apparently considered an argument of
the opposition so profound that the best
tactic was to steer clear of it.
After the re-election and revitalization
of the Bush-administration in the au-
tumn of 2004, the disagreement as to
whether the two first or the third fram-
ing, the scientific and medical progress
or the moral concern, should gain domi-
nance was continued on state level. The
two leading states in stem cell research,
the republican governed California and
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the democratic governed Massachu-
setts, both passed state laws permitting
and offering public funding for research
on human embryonic stem cell.
Forth Framing. Adult Stem Cells as
Nature’s Own Solution?
The first two framings were influential,
but they did not succeed to avoid, neu-
tralize or overtrump the old and antici-
pated ethical considerations. The focal
public debate became a partial revival of
old ethical concerns, a new version of
the debate on embryonic research, but
novel and unique to human stem cells
was the way science itself suggested new
“technical” solutions to the old ethical
concerns. In two subsequent steps sci-
ence partly regained the framing and the
agenda, first by the idea of adult stem
cells as Nature’s own solution, then by
therapeutic cloning as Mankind’s techno-
fix to the ethical challenges. Using the
language of Actor-Network-Theory both
were framed or presented as alternative
points of passage (Christiansen, quoted
by Kater, 2004). The entrepreneurs, the
scientists and their labs partly regained
the scene and the agenda from public
policy and ethical concerns.
The very article in Science that pro-
moted stem cells as the breakthrough of
the year, also pointed to another “aston-
ishing development that occurred in
1999 (and that) may ease the ethical di-
lemma”.
In defiance of decades of accepted
Figure 2. The Ontological Hierarchy of Stem Cells.
Source: The National Institute of Health, Primer, 2002.
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wisdom, researchers in 1999 found that
stem cells from adults retain the youth-
ful ability to become several different
kinds of tissues: Brain cells can become
blood cells, and cells from bone marrow
can become liver (Vogel, 1999: 2238).
If it could be demonstrated that adult
stem cells had the same (or equivalent)
potentials as the embryonic, they would
allow to obtain the advantages of stem
cells without the use of embryonic cells,
and could thus be framed as “Natures
own solution” to the reoccurring ethical
concerns. Even Thomson kept the theo-
retical possibility open: “If it becomes
possible to derive an ES cell line from a
source other than an embryo, ethical
controversies surrounding hES cells
would greatly diminish” (Thomson,
2001). Partly funded and eagerly moni-
tored by politicians sceptical to research
on embryonic stem cells, research-
teams speeded up their work on adult
stem cells. During 2001 examples ap-
pearing to prove the principle were re-
ported continuously (Clark et al., 2001;
Colter et al., 2001; Scolding, 2001). On
June 21, 2002 Science illustrated the plas-
ticity “too good to be true”, … “that stem
cells from a variety of tissues can produce
Figure 3.  The Plasticity of Adult Stem Cells . “Too good to be true?”
Reprinted with permission from Holden & Vogel, SCIENCE 296: 2126-2129 (2002).
Illustration by C. Slayden. Copyright 2002 AAAS.
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progeny in different organs” (Holden and
Vogel, 2002: 2126).
Researchers and scientists did, how-
ever, disagree no less and no less severely
than the bioethicists. The National Insti-
tute of Health’s authoritative and widely
used Primer thus initially reproduced
the old “accepted wisdom” ranking stem
cells in a one-way “ontological” hierar-
chy, which prescribed a moral dilemma
for anyone ascribing a special moral sta-
tus to the embryo. The closer to the bio-
logical origin, the greater the medical
potentials – and the more suspect the
morality!
The N.I.H. has since changed the
primer also in order to reflect the possi-
ble potentials of adult stem cells better.
Figure III was omitted in an update of
3.17.2002 and replaced by the addition
that “until recently, there was little evi-
dence that stem cells from adults could
change course and provide the flexibil-
ity that researchers need in order to ad-
dress all the medical diseases and disor-
ders they would like to. New findings in
animals, however, suggest that even af-
ter a stem cell has begun to specialize, it
may be more flexible than previously
thought”.
Theoretical arguments in favour of
the hierarchical necessity were mostly
voiced by developmental biologists and
embryologists. Typical is Stephen Jay
Gould’s argument for a “progressive
specification and differentiation.”
The very structure of material reality
imposes a principle of trade-offs in
both nature and human affairs… We
have, in short, traded regenerative ca-
pacity for the undeniable evolutionary
advantages of maximal complexity…
Unfortunately, von Bauer’s law, and
nature’s broader structural rules of
trade-off between complexity and flex-
ibility, give us no alternative to embry-
onic stem cells for now (Gould, 2001).
Highly esteemed scientists conceptual-
ised and interpreted the potentiality of
adult stem cells as a closed “theoretical
impossibility” visualised as an “irrevers-
ible hierarchy”, as well as an open “em-
pirical possibility” visualised as an “ema-
nating star”. Different levels of abstrac-
tion and conceptual traditions are at
stake, but the two positions and hypoth-
eses can not both be the whole truth. The
still unsettled disagreement resembles
the state of internal “anomie” often pre-
ceding a new paradigm, more than the
everyday routines of an accepted “nor-
mal-science” (Kuhn, 1962).
Fifth Framing. Therapeutic Cloning
as Mankind’s Techno-fix?
Following the dubious and doubtful
presentation of adult stem cells as Na-
ture’s own solution, cloning and parthe-
nogenesis were soon framed and pre-
sented as Mankind’s own techno-fix so-
lution and a second alternative point of
passage to the relentless moral concerns.
On November 25, 2001, Advanced Cell
Technology (A.C.T.), Worchester, Massa-
chusetts announced to the public that
they had succeeded in creating the first
human embryo using cloning tech-
niques. Two techniques had been used,
both combining a human egg with the
person’s own cells in order to provide
stem cells. A technique á la Dolly re-
placed the genetic material of human
eggs with that of adult cells. Eleven at-
tempts used adult skin cells, eight cumu-
lus cells. None of the eggs with skin cells
survived to divide, whereas three eggs
with cumulus cells divided once or twice
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before they died. The second and most
successful technique was, however, par-
thenogenesis, i.e. a chemical stimulation
of eggs to divide without fertilization.
Twenty-two attempts were made, six
eggs lived and divided for up to five days,
but all died before stem cells ready to be
harvested were formed.
Key players had moved from Geron to
A.C.T, now headed by the former CEO of
Geron Dr. West, and the modus and
moment of going public was no less
orchestrated than Geron’s initial an-
nouncement of the derivation. The trin-
ity of information, i.e. periodicals, press
releases and mass media, was thus in-
tended as a blue print of the initial suc-
cess, but the prestigious Science and Pro-
ceedings of the National Academy of Sci-
ence were substituted by a prepublica-
tion of the January 2002 issue of the
popular Scientific American (2002) and
a “Rapid Communication” in the new
web-journal E-biomed: The Journal of
Regenerative Medicines (Cibelli et al.,
2001). Lacking the scientific backing, the
mass media consequently reported the
whole event as scientifically premature.
Professor I.L. Weismann, a nestor in
stem cell research, denounced the whole
story as a “non-event”. The venture capi-
talists did not respond in any support-
ive way and the intended revival of the
first framing as scientific progress was
once again overruled by moral concerns.
The techniques were identical with the
first steps in reproductive cloning - an
issue highlighted around Christmas the
same year with a series of equally pre-
mature pronouncements of the first hu-
man clone already in uterus. The sug-
gested techno-fix was thus considered
and denied as just another moral prob-
lem: Hubris, playing - or taking the place
of - God. Mankind’s attempt of a techno-
fix creation was dammed as just as of-
fensive as his research on God’s own
creations. The alternative point of pas-
sage was rejected as a new moral prob-
lem, rather than a smart technical solu-
tion to the old moral problems. The ex-
perienced staff was, however, prepared
to counter that. Dr. Ronald Green, the
founding director of Office of Genome
Ethics under the Clinton Administration,
was now Chair of A.C.T.’s own Ethical Ad-
visory Board, and the Boards conclusions
and recommendations were printed side
by side with the reportage in Scientific
American:
…unlike an embryo, a cloned organism
is not the result of fertilization of an egg
by a sperm. It is a new type of biologi-
cal entity never before seen in nature…
we preferred the term “activated egg”,
and we concluded that its characteris-
tics did not preclude its use in work that
might save the lives of children and
adults (Scientific American, 2002).
A.C.T.’ s Ethical Advisory Board was thus
able to expel or disqualify the moral con-
cern as a question of (mis)understand-
ing more than of substance, and as such
to be solved on the level of concepts,
neither in the labs nor on the political
scene. Preceded by the terms “deriva-
tion” and “regenerative medicine” this
conceptual manoeuvre is a third major
example of the “power of definition”
(Wolpe and McGee, 2001). A.C.T.’ s Ethi-
cal Board is just one among many exam-
ples of how U.S. bioethicists, in addition
to the few appointments to public
commities (where they often express
concern), are hired and employed as a
profession on the level of labs and uni-
versities (where they often justify planned
or ongoing research) (Donalson, 2001;
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Elliott, 2001). The supply of well-edu-
cated bioethicists has by far surpassed
that of stem cell lines, and in the absence
of a comprehensive national law in the
US they often serve as “lawmakers” on
the level of the firm. The old maxims of
bioethics still dominating public dis-
course and the new profession of bio-
ethicists increasingly employed in pri-
vate frontline labs are thus drawing and
drawn in each their direction, between
concern and justification.
The Political Ethics of Human
Embryonic Stem Cells
The five framings of human embryonic
stem cells, presented and discussed
above, did not originate and emanate
from the science in the making in the
labs; nor were they orchestrated by a sin-
gle network or a single set of homoge-
neous agents; nor did they succeed each
other successfully rendering the former
superfluous. The two initial framings, as
progress in basic science and hope of
medical cure, were motivated and stirred
by the entrepreneurs to avoid the expe-
riences from the public debate follow-
ing previous progress in biotechnology,
but the public and political debate over-
ruled the intention and strategy by the
third framing as a moral concern. The
two remaining framings representing
adult stem cells and therapeutic cloning
as alternative points of passage and so-
lutions, redirected the debate to the level
of the labs and the entrepreneurs, but
they did not succeed to dominate and
even less to close the debate – at least
up until now.
The five framings do still coexist in an
unsettled and unclosed tension, but the
framings and their implications differ in
such a profound way, that the question
as to whether (and if so, how) they can
really all refer back to the very same
“clonogenic cells” nearly poses itself. Is
the diversity of framings just a mere and
fair reflection of the still un-described
potentials inherent in the unique cells?
Is the multitude of framings better inter-
preted as an expression of the many ex-
ternal interests involved in the political
decisions? Should the disparity between
the framings rather be seen as an echo
of the plurality and relativism in post-
modern optics? Might the many, still
competing, framings be a mere conse-
quence of the fact that the unique cells
only recently were constituted as object
for science, a question of time soon to
be resolved? Or could it be that there is
no one single and well-defined biologi-
cal entity behind the five framings?
Professions and experts have often
claimed a normative priority or even
precedents on behalf of “their” framing:
for science as the necessary precondi-
tion; for medicine as the ultimate goal;
for ethics as the absolute limit to all the
others; for adult stem cells as the ulti-
mate and for the techno-fix as the smart-
est solution. None of the framings have,
however, attained any such priority. All
have been part of an encounter for a
truthful understanding and a fair evalu-
ation, but none of them have had the
power or influence to prescribe their
understanding as unequivocal. The
framings never posed a single agenda;
nor did they determine a corresponding
evaluation. Political interests and com-
promises have consequently over-deter-
mined, tinted and intermixed, the five
framings from the very beginning. The
presentation of the scientific break-
through was co-determined by the re-
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quirements for funding and patents. The
medical hope was embedded in general
changes of life-style. Ethical recommen-
dations were altered according to politi-
cal appointments. Adult stem cells and
cloning/parthenogenesis were instantly
presented to politics as possible solu-
tions to the ethical concerns.
Sheila Jasanoff has mapped and em-
phasized substantial national differences
in the American, British and German
regulation of biotechnology (Jasanoff,
1995). Unrelated shifts of governments
in the three nations during the early
years of human embryonic stem cells
have, however, shaped noteworthy shifts
within the national regulations. The
U.S.A. has turned towards a more restric-
tive and Germany towards a more per-
missive regulation whereas Great Britain
represents a national continuity.
The British continuity is firmly rooted
in the nation’s customary scientific self-
understanding and institutionalized
through the Warnock-Committee, the
subsequent Human Fertilisation and
Embryology Act and its corresponding
executive body The Human Fertilisation
& Embryology Authority (Mulkay, 1997).
Within this framework Tony Blair’s new
Labour-government could turn to The
Chief Medical Officer for a delimited and
authoritative examination. Neither gov-
ernment nor the parliamentary major-
ity had problems in following the pre-
dictable recommendation that “research
using embryos […] to increase under-
standing about human disease and dis-
orders and their cell-based treatment
should be permitted subject to the con-
trols of the Human Fertilisation and
Embryology Act”. The only additional
step needed was the Human reproduc-
tive Cloning Act of 2001 that prohibited
“the placing in a woman of a human
embryo which has been created other-
wise than by fertilization” i.e. by repro-
ductive cloning.
Following the President’s broadcasted
address on August 9, 2001, the U.S.A. im-
plemented a new advisory structure. An
Executive Order of Nov. 28 established
The President’s Council on Bioethics
headed by the well-known conservative
bioethicist Professor Leon Kass (Kass,
2001). Seventeen additional members
were appointed on January 16, 2002. The
President addressed them the following
day (Bush, 2002) and the Council’s report
Human Cloning and Human Dignity: An
Ethical Inquiry was published in July the
same year. The Council was unanimous
to refuse “cloning-to-produce-children”
(reproductive cloning), but split regard-
ing “cloning-for-biomedical-research”
(therapeutic cloning). A majority of ten
recommended “a four-year morato-
rium”, whereas a minority of seven rec-
ommended “regulation on the use of
cloned embryos for biomedical re-
search” (The President’s Council on
Bioethics, 2002). Accordance between
the President’s policy and (the majority
of) his ethical advisors was thus re-es-
tablished. A recent reconstruction of the
decision making process and its proce-
dure by Alta Charo, a member of Presi-
dent Clinton’s National Bioethics Advi-
sory Commission (1996-2001), concludes
that what distinguishes President Bush’s
new Council from the former “is not that
it incorporates politics into its work, but
that it does so with a concerted effort to
promote a particular political philosophy,
and pursues this philosophy through its
membership and its staffing”. Her final
deep sigh that the most vibrant and en-
during debates “are not at all about the
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ethics of biology or medicine, but the
ethics of governance” (Charo, 2004: 308,
312) is in full harmony with the above
findings.
Following Helmut Kohl’s CDU-gov-
ernment Gerhard Schroeder’s new SPD-
government initiated the reverse shift to-
wards a more permissive policy taken in
Germany. The new Nationaler Ethikrat
was appointed on April 25, 2001. Ad-
dressed by the Chancellor at its first
meeting on June 8 (Schroeder, 2001) and
its report Stellungnahme zum Import
menschlicher embryonaler Stamzellen
was published the following summer.
Fifteen members voted in favour of “a
provisional and temporary import of
human embryonic stem cells on hard
conditions”, whereas ten members voted
for “a provisional refusal of import of
stem cells” (Nationaler Ethikrat, 2002).
Accordance between the Chancellor’s
policy and (the majority of) his ethical
advisors was thus re-established.
The unchanged British policy, the U.S.
shift toward a more restrictive and the
German toward a more permissive
policy, are good illustrations of how ef-
fected even the principles of bioethics
have been by national differences and
political conjunctures. Bioethics often
argue in a strong rhetoric and with ab-
solute arguments, but they have never
been unambiguous, nor a decisive or
even superseding argument in political
decisions. Shifting politicians have re-
peatedly appointed their bioethical ad-
visors in accordance with predeter-
mined policies. Bioethics has always also
been political. The (Christian) argument
from status and the (Kantian) maxim of
means-ends have been powerful rhe-
torical tools, but pragmatic and utilitar-
ian ethics have had a greater impact on
political decisions. The considerations of
political bioethics have gradually turned
from the status of the biological sub-
stances and general maxims towards the
more comprehensive questions of soci-
ety’s justice and the individual’s identity.
Possible consequences for society at
large, i.e. the possibility of a more hier-
archical and competitive post-human
world, and the emergence of a new, lib-
eral and unintended eugenics, have
gained increased attention. Fukuyama,
a U.S. neo-liberal and a member of the
Bush Council, argues that what ought to
be the real cause of worry are the “mon-
sters we will soon be capable of creat-
ing,” not the sources of stem cells. “The
posthuman world could be one that is
far more hierarchical and competitive
than the one that currently exists, and full
of social conflicts as a result” (Fukuyama,
2002: 91, 218). Jürgen Habermas (2003),
a German philosopher in the tradition
of the Frankfurt School, questions the
identity of individuals whose genetic
makeup has been pre-selected or pre-
manipulated as an issue of “Gattungs-
ethik”.
Most policy decisions and regulations
have been open and pragmatic enough
to enable two apparently opposed, but
coexisting critiques: one aimed at the
use of dual or double “moral” standards
voiced mainly by religious communities,
and another aimed at the too restrictive
regulations and voiced mainly by the
scientific communities and business.
The Presidential decision permitted
the use of old embryonic stem cell lines
dating back before the speech of August
9, 2001 “where the life and death deci-
sion has already been made”. The new
German Law permitted the use of im-
ported stem cell lines. Already existing
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and imported cell lines are both prag-
matic loopholes, without which the criti-
cism for too restrictive policies would
have been even more vociferous, but
political regulations have nonetheless
increasingly been used to excuse and
explain away disappointed or post-
poned hopes and expectations. The ini-
tial framings are thus twisted to the ar-
gument that politicians giving too many
concessions to the ethical concerns are
the prime cause of the still unfulfilled
expectations. The disappointment is
thus presented as a matter of time, not
of principle; a question of delay, not of
unsolvable problems. Had science only
had the freedom to follow its course,
promises and expectations would al-
ready have been fulfilled! A hypotheti-
cal bogey is thus turned into a partial
excuse.
Entity or State?
Representing a radical version of the “ex-
tended social constructivism”, presented
earlier by Pinch and Bijker, John Law has
drawn the methodological implication
that “… from the standpoint of the net-
work those elements that are human or
social do not necessarily differ in kind
from those that are natural and techno-
logical” […] “it makes sense to treat
natural and social adversaries in terms
of the same analytical vocabulary” (Law,
1989: 114). Yet, the difference between
Bijker and Pinch’s use of the term “fram-
ing” to indicate different designs and in-
ventions and the five framings of what
is expected to be the same biological en-
tity, discussed here, suggests important
differences between the design of “tech-
nological artefacts” (as the bicycle and
Bakelite) and the derivation of an “en-
tity of nature” (as embryonic stem cells).
Both are open to interpretative “flexibil-
ity”, but natural “facts” appear less open
to design than technological “artefacts”
and social “constructs”, and it appears
that natural entities can be “stabilized”
without a closure of the debate and con-
troversy over them.
Culminating in the so called “science
war”, representatives of the hard sci-
ences have repeatedly criticized radical
social constructivism as mere relativis-
tic or even subjectivistic, as the prec-
edence of sociology of knowledge over
epistemology, and thus also of power
over truth. A recent review article by the
geneticist and system-biologist Dov
Zipori suggests, however, “state” rather
than “entity” as the real “nature” or true
interpretation of embryonic stem cells.
The transient stem cell state, termed the
“stem state”, may be assumed by any cell
and the persistent search for specific
genes expressed by any stem cells, might
thus be futile, doomed to become un-
successful. Following Zipori, stem cells
are just a “molecular configuration”
without permanent characteristics,
which should be identified or predicted
by system-biology tools, i.e. overall ge-
nomic and proteomic analysis coupled
with mathematical modeling (Zipori,
2004: 873).
Zipori’s system-biological reinterpre-
tation of embryonic stem cells, empha-
sizing the state rather than the entity, the
biological environment rather than the
genetic make-up, represents an ironic
twist and implicit concession to the radi-
cal social constructivists and offers a
possible explanation to the diversity of
framings. Stem cells as just a state in-
stead of a specific type of cells, makes the
apparent “triviality” of their derivation
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less mysterious. Stem cells as “stemness”
dissolve the alleged differences in poten-
tiality between embryonic and adult
stem cells, and dissolute the alternative
between embryonic stem cells as either
an ontological hierarchy or pure plastic-
ity dissolute. The moral discussion,
which presupposes or ascribes a specific
“ethical” nature or validity of embryonic
as opposed to adult stem cells, appears
even more ungrounded and futile than
implied above. Science’s editorial stand
back in 1999 that stem cells “forces sci-
entists to reconsider fundamental ideas
about how cells grow up” (Vogel, 1999)
might have more profound and far-
reaching implications than fainted and
glimpsed hitherto.
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Notes
1 Further patents, licensing policies, the
new importance of patents after the U.S.
Presidential decision of August 9, 2001,
and Geron’s later patent strategy in coop-
eration with The Roslin Institute are de-
scribed in Franklin (2003) and Rohrbaugh
(2003).
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